Valuation: Kura Oncology, Inc.

Capitalization 644M 613M 578M 511M 912M 55.78B 1.01B 6.88B 2.55B 23.32B 2.41B 2.37B 97.91B P/E ratio 2024 *
-4.62x
P/E ratio 2025 * -4.45x
Enterprise value 248M 236M 223M 197M 352M 21.51B 390M 2.65B 983M 8.99B 931M 912M 37.75B EV / Sales 2024 *
4.28x
EV / Sales 2025 * 2.44x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 week-4.28%
Current month+4.68%
1 month+15.32%
3 months-47.99%
6 months-56.99%
Current year-4.94%
More quotes
1 week
7.96
Extreme 7.96
8.85
1 month
7.20
Extreme 7.2
9.16
Current year
6.98
Extreme 6.98
9.16
1 year
6.98
Extreme 6.98
24.17
3 years
6.98
Extreme 6.98
24.17
5 years
6.35
Extreme 6.35
43.00
10 years
2.50
Extreme 2.5
43.00
More quotes
Director TitleAgeSince
Chief Executive Officer 56 2014-08-21
Chief Tech/Sci/R&D Officer - 2025-01-01
Chief Tech/Sci/R&D Officer - 2025-01-01
Manager TitleAgeSince
Chairman 56 2015-02-28
Director/Board Member 66 2015-04-26
Director/Board Member 56 2015-10-13
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
0.00%-4.28%-59.84%-40.65% 644M
-0.77%-2.20%+8.72%+94.68% 118B
-0.10%-5.13%-28.95%+6.77% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+30.72%-27.59% 28.73B
+2.38%+3.29%+55.74%+4.84% 24.63B
+4.61%+2.25%+11.97%-39.14% 23.61B
-2.06%+6.27%+321.50%+903.29% 15.76B
+0.81%-0.80%+168.76%+230.46% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average +0.13%+0.53%+55.69%+124.20% 34.98B
Weighted average by Cap. -0.26%-1.16%+32.25%+93.12%
See all sector performances

Financials

2024 *2025 *
Net sales 57.96M 55.18M 52.04M 45.96M 82.12M 5.02B 91.13M 620M 230M 2.1B 217M 213M 8.81B 82.44M 78.48M 74.02M 65.38M 117M 7.14B 130M 881M 327M 2.99B 309M 303M 12.54B
Net income -153M -146M -138M -122M -217M -13.29B -241M -1.64B -608M -5.56B -575M -564M -23.33B -165M -157M -148M -131M -233M -14.27B -259M -1.76B -652M -5.97B -617M -605M -25.04B
Net Debt -396M -377M -355M -314M -561M -34.27B -622M -4.23B -1.57B -14.33B -1.48B -1.45B -60.16B -443M -421M -397M -351M -627M -38.34B -696M -4.73B -1.75B -16.03B -1.66B -1.63B -67.29B
More financial data * Estimated data
Logo Kura Oncology, Inc.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Employees
142
More about the company
Date Price Change Volume
25-02-14 8.280 $ 0.00% 815,081
25-02-13 8.280 $ -0.84% 699,131
25-02-12 8.350 $ +0.12% 805,856
25-02-11 8.340 $ -5.12% 1,928,345
25-02-10 8.790 $ +1.62% 1,106,788

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
8.280USD
Average target price
27.69USD
Spread / Average Target
+234.45%
Consensus

Quarterly revenue - Rate of surprise